Citable filing context
IEX's research view summarizes recent SEC filing context, starting with management_change from Aug 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 17, 2026 | management_change | L. Paris Watts-Stanfield resigned from the Board of Directors of IDEX Corporation, effective August 13, 2026. |
| Jul 29, 2026 | earnings | IDEX Corporation reported Q2 2026 record sales of $921 million and raised its full-year 2026 financial guidance. |
| May 8, 2026 | other | IDEX Corp held its annual meeting, electing four Class I directors and approving executive compensation and auditor ratification. |
| Jul 29, 2026 | Guidance: adjusted_diluted_eps | 8.70 to 8.85 |
| Jul 29, 2026 | Guidance: adjusted_diluted_eps | 2.20 to 2.25 |
| Jul 29, 2026 | Guidance: organic_sales_growth | 5.00 to 6.00 |
| Jul 29, 2026 | mda_quarterly | IDEX Corporation reported strong second-quarter 2026 results, with net sales of $920.6 million, a 6% increase driven by 5% organic growth. Performance was bolstered by robust demand in the Health & Science Technologies (HST) segment, specifically within data center, semiconductor, and space and defense markets. The company also benefited from the resolution of International Emergency Economic Powers Act (IEEPA) tariffs, which provided a net positive impact on gross margin and earnings per share, despite a $14.7 million reduction in net sales from associated customer rebates. Operating income rose 6% to $199.9 million, while adjusted diluted EPS grew 12% to $2.32. Profitability was supported by volume leverage and productivity improvements, though partially offset by unfavorable product mix. The company maintains a solid liquidity position, ending the quarter with $621.3 million in cash and $529.6 million in available revolving credit capacity. Capital allocation remains focused on shareholder returns, with $77.1 million in share repurchases and $53.9 million in dividends during the quarter. Management continues to monitor macroeconomic risks, including global trade policies, inflationary pressures, and potential shifts in AI-driven market demand, while maintaining a disciplined approach to organic and inorganic growth through strategic acquisitions like Micro-LAM. |
| Apr 29, 2026 | mda_quarterly | IDEX reported first-quarter 2026 net sales of $886.9 million, a 9% increase over the prior year, with organic growth of 5%. Diluted earnings per share rose 28% to $1.61. Growth was primarily driven by the Health & Science Technologies segment, which benefited from AI-driven demand in data center power and semiconductor markets, alongside strength in space and defense. The Fluid & Metering Technologies segment saw volume gains in municipal water and mining, offset by declines in chemical and industrial markets. Fire & Safety/Diversified Products experienced lower volumes in dispensing due to project timing. Positive pricing across all segments and operational productivity gains supported margins, though the FMT segment recorded $4.8 million in asset impairments. Strategic expansion included the acquisition of Micro-LAM, Inc. to enhance optics technologies. While the company is monitoring new tariffs following a U.S. Supreme Court ruling, no material impact has occurred. IDEX generated $86 million in free cash flow and returned capital via $76.3 million in share repurchases and $52.8 million in dividends. Liquidity remains robust with $517.2 million available under its revolving credit facility. |
Source: SEC EDGAR filing text and events; period Aug 17, 2026; filed Aug 17, 2026.
IEX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.